Xenobiotic metabolizing enzyme gene polymorphisms predict response to lung volume reduction surgery

Respiratory Research

Volumn 8, Issue , 2007, Pages

  Hersh, Craig P ^a,b   DeMeo, Dawn L ^a,b   Reilly, John J ^a,b   Silverman, Edwin K ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHX1 PROTEIN, HUMAN; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMPHYSEMA; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; LUNG RESECTION; MALE; METHODOLOGY; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICS; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; EMPHYSEMA; EPOXIDE HYDROLASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; PNEUMONECTOMY; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 38449092163     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-8-59     Document Type: Article

References (38)

1. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003, 348:2059-2073. 10.1056/NEJMoa030287, 12759479.
2. National Emphysema Treatment Trial Research Group Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001, 345:1075-1083. 10.1056/NEJMoa11798, 11596586, National Emphysema Treatment Trial Research Group.
3. Celedon JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, DeMeo DL, Reilly JJ, Kwiatkowski DJ, Chapman HA, Laird N, Sylvia JS, Hernandez M, Speizer FE, Weiss ST, Silverman EK. The transforming growth factor-{beta}1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 2004, 13:1649-1656. 10.1093/hmg/ddh171, 15175276.
4. Demeo DL, Mariani TJ, Lange C, Srisuma S, Litonjua AA, Celedon JC, Lake SL, Reilly JJ, Chapman HA, Mecham BH, Haley KJ, Sylvia JS, Sparrow D, Spira AE, Beane J, Pinto-Plata V, Speizer FE, Shapiro SD, Weiss ST, Silverman EK. The SERPINE2 Gene Is Associated with Chronic Obstructive Pulmonary Disease. Am J Hum Genet 2006, 78:253-264. 1380249, 16358219, 10.1086/499828.
5. Hersh CP, Demeo DL, Lange C, Litonjua AA, Reilly JJ, Kwiatkowski D, Laird N, Sylvia JS, Sparrow D, Speizer FE, Weiss ST, Silverman EK. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol 2005, 33:71-78. 10.1165/rcmb.2005-0073OC, 15817713.
6. Hersh CP, Demeo DL, Lazarus R, Celedon JC, Raby BA, Benditt JO, Criner G, Make B, Martinez FJ, Scanlon PD, Sciurba FC, Utz JP, Reilly JJ, Silverman EK. Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:977-984. 10.1164/rccm.200509-1452OC, 16456143.
7. Demeo DL, Hersh CP, Hoffman EA, Litonjua AA, Lazarus R, Sparrow D, Benditt JO, Criner G, Make B, Martinez FJ, Scanlon PD, Sciurba FC, Utz JP, Reilly JJ, Silverman EK. Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med 2007, 176:42-48. 10.1164/rccm.200612-1797OC, 17363767.
8. The National Emphysema Treatment Trial Research Group Rationale and design of The National Emphysema Treatment Trial: a prospective randomized trial of lung volume reduction surgery. Chest 1999, 116:1750-1761. 10.1378/chest.116.6.1750, 10593802, The National Emphysema Treatment Trial Research Group.
9. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998, 113:619-624.
10. American Thoracic Society Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995, 152:1107-1136. American Thoracic Society.
11. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012. 10.1056/NEJMoa021322, 14999112.
12. Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann G, Fishman A, DeCamp MM, Benditt J, Sciurba F, Make B, Mohsenifar Z, Diaz P, Hoffman E, Wise R. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 2006, 173:1326-1334. 10.1164/rccm.200510-1677OC, 16543549.
13. The International HapMap Project. Nature 2003, 426:789-796. 10.1038/nature02168, 14685227.
14. SeattleSNPs. , http://pga.gs.washington.edu/
15. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005, 37:1217-1223. 10.1038/ng1669, 16244653.
16. Naunheim KS, Wood DE, Mohsenifar Z, Sternberg AL, Criner GJ, DeCamp MM, Deschamps CC, Martinez FJ, Sciurba FC, Tonascia J, Fishman AP. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006, 82:431-443. 10.1016/j.athoracsur.2006.05.069, 16888872.
17. The R Project for Statistical Computing. , http://www.r-project.org/
18. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265. 10.1093/bioinformatics/bth457, 15297300.
19. Gauderman WJ. Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med 2002, 21:35-50. 10.1002/sim.973, 11782049.
20. Marinescu VD, Kohane IS, Riva A. MAPPER: a search engine for the computational identification of putative transcription factor binding sites in multiple genomes. BMC Bioinformatics 2005, 6:79. 1131891, 15799782, 10.1186/1471-2105-6-79.
21. Berger RL, Wood KA, Cabral HJ, Goodnight-White S, Ingenito EP, Gray A, Miller J, Springmeyer SC. Lung volume reduction surgery: a meta-analysis of randomized clinical trials. Treat Respir Med 2005, 4:201-209. 10.2165/00151829-200504030-00004, 15987235.
22. Cheng YJ, Chan KC, Chien CT, Sun WZ, Lin CJ. Oxidative stress during 1-lung ventilation. J Thorac Cardiovasc Surg 2006, 132:513-518. 10.1016/j.jtcvs.2006.03.060, 16935103.
23. Fan VS, Ramsey SD, Make BJ, Martinez FJ. Physiologic variables and functional status independently predict COPD hospitalizations and emergency department visits in patients with severe COPD. COPD 2007, 4:29-39.
24. He JQ, Connett JE, Anthonisen NR, Pare PD, Sandford AJ. Glutathione S-transferase variants and their interaction with smoking on lung function. Am J Respir Crit Care Med 2004, 170:388-394. 10.1164/rccm.200312-1763OC, 15184197.
25. Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi T, Takahashi H, Fukuchi Y, Ouchi Y. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax 1999, 54:693-696.
26. Yim JJ, Yoo CG, Lee CT, Kim YW, Han SK, Shim YS. Lack of association between glutathione S-transferase P1 polymorphism and COPD in Koreans. Lung 2002, 180:119-125. 10.1007/s004080000086, 12172904.
27. Mullins DN, Crawford EL, Khuder SA, Hernandez DA, Yoon Y, Willey JC. CEBPG transcription factor correlates with antioxidant and DNA repair genes in normal bronchial epithelial cells but not in individuals with bronchogenic carcinoma. BMC Cancer 2005, 5:141. 1310620, 16255782, 10.1186/1471-2407-5-141.
28. Raaka S, Hassett C, Omiencinski CJ. Human microsomal epoxide hydrolase: 5'-flanking region genetic polymorphisms. Carcinogenesis 1998, 19:387-393. 10.1093/carcin/19.3.387, 9525271.
29. Huang TH, Razmovski-Naumovski V, Kota BP, Lin DS, Roufogalis BD. The pathophysiological function of peroxisome proliferator-activated receptor-gamma in lung-related diseases. Respir Res 2005, 6:102. 1242255, 16153299, 10.1186/1465-9921-6-102.
30. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 1994, 3:421-428. 10.1093/hmg/3.3.421, 7516776.
31. Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR, Pare PD. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med 2001, 163:469-473.
32. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997, 350:630-633. 10.1016/S0140-6736(96)08061-0, 9288046.
33. Shaw AD, Vaporciyan AA, Wu X, King TM, Spitz MR, Putnam JB, Dickey BF. Inflammatory gene polymorphisms influence risk of postoperative morbidity after lung resection. Ann Thorac Surg 2005, 79:1704-1710. 10.1016/j.athoracsur.2004.10.010, 15854959.
34. Podgoreanu MV, Schwinn DA. New paradigms in cardiovascular medicine: emerging technologies and practices: perioperative genomics. J Am Coll Cardiol 2005, 46:1965-1977. 10.1016/j.jacc.2005.08.040, 16325027.
35. Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet 2006, 7:781-791. 10.1038/nrg1916, 16983374.
36. Hirschhorn JN, Altshuler D. Once and again-issues surrounding replication in genetic association studies. J Clin Endocrinol Metab 2002, 87:4438-4441. 10.1210/jc.2002-021329, 12364414.
37. Miller JD, Berger RL, Malthaner RA, Celli BR, Goldsmith CH, Ingenito EP, Higgins D, Bagley P, Cox G, Wright CD. Lung volume reduction surgery vs medical treatment: for patients with advanced emphysema. Chest 2005, 127:1166-1177. 10.1378/chest.127.4.1166, 15821191.
38. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003, 361:865-872. 10.1016/S0140-6736(03)12715-8, 12642066.